ArticleCardiology and therapy2026
Utilization Patterns and Barriers to Sodium-Glucose Cotransporter-2 Inhibitor Prescription in Patients with Heart Failure: Real-World Evidence from Saudi Arabia.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended as foundational therapy for patients with heart failure (HF) across all ejection fractions; however, real-world adoption remains inconsistent, and data from Middle Eastern health systems are limited. This study aimed to assess real-world utilization of SGLT2i among patients with HF in Saudi Arabia and to identify clinical factors associated with prescribing and outcomes.
methodsWe conducted a multicenter retrospective cohort study of adult patients with HF receiving longitudinal care at tertiary cardiac centers between January 2016 and December 2024 in Saudi Arabia. HF phenotypes included reduced, mildly reduced, preserved, and improved ejection fraction. The primary outcome was SGLT2i use during follow-up. Multivariable logistic regression identified factors associated with prescribing. Exploratory outcomes included HF hospitalization and all-cause mortality.
resultsAmong 1081 patients with HF (median age 66 years [IQR 56-76]; 50.8% women), 626 (57.9%) received an SGLT2i. Utilization uptake increased over time but was lower in HF with preserved versus reduced ejection fraction (adjusted odds ratio [aOR] 0.30; 95% CI 0.20-0.43). Diabetes mellitus (aOR 2.29; 95% CI 1.60-3.29) and greater baseline guideline-directed medical therapy optimization (aOR per additional class 1.31; 95% CI 1.13-1.51) were independently associated with use, whereas advanced chronic kidney disease (eGFR < 30 ml/min/1.73 m
conclusionsIn this real-world cohort, SGLT2i use was heterogeneous and influenced by HF phenotype, renal function, comorbidity burden, and baseline therapy, highlighting persistent gaps in evidence-based HF care.
Indexed as
Identifiers
42287496What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.